Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Steven Larosa

Title(s)Clinical Professor (Voluntary), Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys. Transpl Immunol. 2025 May; 90:102215. de Necochea Campion R, Pesqueira M, Vallejos P, McCullough C, Bloesch A, LaRosa SP. PMID: 40024312.
      View in: PubMed   Mentions:
    2. Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin. PLoS One. 2022; 17(7):e0272377. Gooldy M, Roux CM, LaRosa SP, Spaulding N, Fisher CJ. PMID: 35901224; PMCID: PMC9333444.
      View in: PubMed   Mentions:
    3. Removal of COVID-19 Spike Protein, Whole Virus, Exosomes, and Exosomal MicroRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients With COVID-19 Infection. Front Med (Lausanne). 2021; 8:744141. Amundson DE, Shah US, de Necochea-Campion R, Jacobs M, LaRosa SP, Fisher CJ. PMID: 34692735; PMCID: PMC8531584.
      View in: PubMed   Mentions:
    4. Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer's Disease Using Antiherpetic Drugs. J Gerontol A Biol Sci Med Sci. 2020 05 22; 75(6):1058-1060. Goldschmidt-Clermont PJ, Volinsky FG, LaRosa SP, Gilbert JR, Periçak-Vance MA. PMID: 31175818.
      View in: PubMed   Mentions:
    5. Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials. Crit Care Med. 2016 Aug; 44(8):1461-7. Yende S, Austin S, Rhodes A, Finfer S, Opal S, Thompson T, Bozza FA, LaRosa SP, Ranieri VM, Angus DC. PMID: 26992066; PMCID: PMC4949079.
      View in: PubMed   Mentions:
    6. Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media. PLoS One. 2014; 9(12):e114242. McCrea K, Ward R, LaRosa SP. PMID: 25469782; PMCID: PMC4254995.
      View in: PubMed   Mentions:
    7. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*. Crit Care Med. 2014 Mar; 42(3):504-11. Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, Larosa SP, Laterre PF, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. PMID: 24335445.
      View in: PubMed   Mentions:
    8. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013 Sep; 41(9):2069-79. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I. PMID: 23979365.
      View in: PubMed   Mentions:
    9. Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? Am J Respir Crit Care Med. 2013 May 15; 187(10):1041-3. Opal SM, LaRosa SP. PMID: 23675711.
      View in: PubMed   Mentions:
    10. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013 Mar 20; 309(11):1154-62. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, ACCESS Study Group. PMID: 23512062.
      View in: PubMed   Mentions:
    11. Drotrecogin alfa (activated) in severe sepsis--authors' reply. Lancet Infect Dis. 2013 Feb; 13(2):110-1. Kalil AC, LaRosa SP. PMID: 23347628.
      View in: PubMed   Mentions:
    12. Immune aspects of sepsis and hope for new therapeutics. Curr Infect Dis Rep. 2012 Oct; 14(5):474-83. Larosa SP, Opal SM. PMID: 22851006.
      View in: PubMed   Mentions:
    13. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis. 2012 Sep; 12(9):678-86. Kalil AC, LaRosa SP. PMID: 22809883.
      View in: PubMed   Mentions:
    14. Clinical and laboratory diagnosis of central nervous system histoplasmosis. Am J Med. 2012 Oct; 125(10):e1-2. Ranganath S, McGhie TA, LaRosa S, Lehman W, Fader R. PMID: 22795819.
      View in: PubMed   Mentions:
    15. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock. 2011 Oct; 36(4):327-31. Kalil AC, LaRosa SP, Gogate J, Lynn M, Opal SM, Eritoran Sepsis Study Group. PMID: 21701421.
      View in: PubMed   Mentions:
    16. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Rev Anti Infect Ther. 2011 May; 9(5):507-20. Tidswell M, LaRosa SP. PMID: 21609262.
      View in: PubMed   Mentions:
    17. Biomarkers: the future. Crit Care Clin. 2011 Apr; 27(2):407-19. LaRosa SP, Opal SM. PMID: 21440209.
      View in: PubMed   Mentions:
    18. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1561-8. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S, CAPTIVATE Trial Group. PMID: 21297074.
      View in: PubMed   Mentions:
    19. Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect. 2010 Oct; 16(10):1576-8. Chan PA, Connell NT, Gabonay AM, Westley B, Larkin JM, LaRosa SP, Chapin K, Mermel L. PMID: 20218988.
      View in: PubMed   Mentions:
    20. Activated protein C for H1N1 influenza? More work to do! Crit Care. 2010; 14(3):156. LaRosa SP. PMID: 20497609; PMCID: PMC2911698.
      View in: PubMed   Mentions:
    21. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010 Jan; 38(1):72-83. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM, Eritoran Sepsis Study Group. PMID: 19661804.
      View in: PubMed   Mentions:
    22. Year in review 2008: Critical Care--sepsis. Crit Care. 2009; 13(5):224. Opal SM, LaRosa SP. PMID: 19886974; PMCID: PMC2784335.
      View in: PubMed   Mentions:
    23. At the heart of the matter. Am J Med. 2009 Apr; 122(4):335-7. Holubar M, Connor M, LaRosa SP, Singh A. PMID: 19332226.
      View in: PubMed   Mentions:
    24. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care. 2009; 13(2):R36. Laterre PF, Opal SM, Abraham E, LaRosa SP, Creasey AA, Xie F, Poole L, Wunderink RG. PMID: 19284881; PMCID: PMC2689471.
      View in: PubMed   Mentions:
    25. Sepsis strategies in development. Clin Chest Med. 2008 Dec; 29(4):735-47, x-xi. LaRosa SP, Opal SM. PMID: 18954707.
      View in: PubMed   Mentions:
    26. Drotrecogin alfa (activated) in severe sepsis. N Engl J Med. 2006 Jan 05; 354(1):94-6; author reply 94-6. LaRosa SP. PMID: 16395833.
      View in: PubMed   Mentions:
    27. Use of corticosteroids in the sepsis syndrome: what do we know now? Cleve Clin J Med. 2005 Dec; 72(12):1121-7. LaRosa SP. PMID: 16392726.
      View in: PubMed   Mentions:
    28. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis. 2006 Jan; 10(1):25-31. LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ. PMID: 16290015.
      View in: PubMed   Mentions:
    29. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin. 2005 Jul; 21(3):433-48. LaRosa SP, Opal SM. PMID: 15992666.
      View in: PubMed   Mentions:
    30. Fever, chills, and chest radiographic infiltrates in a middle-aged woman. Cleve Clin J Med. 2005 May; 72(5):367-9, 373-4. Choure AJ, Shrestha RK, Larosa SP, Mehta AC. PMID: 15929451.
      View in: PubMed   Mentions:
    31. What's new in antibiotics? Dermatol Clin. 2005 Apr; 23(2):301-12. Padmanabhan RA, Larosa SP, Tomecki KJ. PMID: 15837156.
      View in: PubMed   Mentions:
    32. Antibiotics: what's new? Cutis. 2004 May; 73(5 Suppl):10-4. LaRosa SP, Tomecki KJ. PMID: 15182159.
      View in: PubMed   Mentions:
    33. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock. 2004 Mar; 21(3):222-9. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. PMID: 14770034.
      View in: PubMed   Mentions:
    34. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med. 2003 Sep; 31(9):2291-301. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D. PMID: 14501959.
      View in: PubMed   Mentions:
    35. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis. 2003 Jul 01; 37(1):50-8. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR. PMID: 12830408.
      View in: PubMed   Mentions:
    36. Conflict of interest: authorship issues predominate. Arch Intern Med. 2002 Jul 22; 162(14):1646; author reply 1646. LaRosa SP. PMID: 12123411.
      View in: PubMed   Mentions:
    37. Sepsis: menu of new approaches replaces one therapy for all. Cleve Clin J Med. 2002 Jan; 69(1):65-73. Larosa SP. PMID: 11811722.
      View in: PubMed   Mentions:
    38. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 08; 344(10):699-709. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. PMID: 11236773.
      View in: PubMed   Mentions:
    39. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis. 1999 Feb; 28(2):240-6. Gordon SM, LaRosa SP, Kalmadi S, Arroliga AC, Avery RK, Truesdell-LaRosa L, Longworth DL. PMID: 10064238.
      View in: PubMed   Mentions:
    Steven's Networks
    Concepts (197)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California